Author: Ken Dropiewski

ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action

—Largest randomized data set to date on bioadaptor, with a complex patient population of 2,400 compared to a DES— —Primary endpoint of target lesion failure (TLF) non-inferiority at twelve months was met with a low event rate for DynamX despite increased patient complexity— —Pre-specified landmark analysis shows statistically significant reduction […]

Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress

ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia.

Vasa Therapeutics Announces Initiation of Phase 1 First-in-Human Clinical Trial of VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction

Vasa Therapeutics granted MHRA Clinical Trial Authorization (CTA) for VS-041 for the treatment of heart failure with preserved ejection fraction (HFpEF) Company’s seed funding extended to $11M ENCINITAS, Calif. and WROCLAW, Poland, Sept. 3, 2024 /PRNewswire/ — Vasa Therapeutics (“Vasa”),…

Recor Medical Endorses European Society of Cardiology’s New Guidelines for Management of Hypertension

The new ESC Guidelines for Management of Elevated Blood Pressure and Hypertension were presented at the ESC Congress in London and reinforce the safety and effectiveness of renal denervation, recommending its consideration as a treatment option to improve uncontrolled hypertension. PALO…

LifeTech Scientific Corporation Announced 2024 Interim Results: International Business Increased by 30%, Net Profit Margin Attributable to Owners of the Company Reached 35.8%

SHENZHEN, China, Aug. 30, 2024 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “LifeTech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its…

ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data

Hot Line Sessions to Feature Results from Investigational FINEARTS-HF Study in Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Pooled, Exploratory Analysis from Three Pivotal Phase III Trials Exploring Finerenone on Cardio-Kidney Outcomes Detailed data from the Phase III FINEARTS-HF trial that investigated KERENDIA® (finerenone) in patients with heart […]